


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-12. (Canceled)


13. (Original) A compound having the formula:



or a pharmaceutically acceptable salt thereof,

being (i) monosubstituted and having a first substituent present at the 5, 7, or 9 position, (ii) disubstituted and having a first substituent present at the 5 position and a second substituent present at the 9 position, (iii) disubstituted and having a first substituent present at the 7 position and a second substituent present at the 9 position, or (iv) disubstituted and having a first substituent present at the 5 position and a second substituent present at the 7 position;

wherein the first and second substituent, when present, are independently alkyl, halogen, hydroxy, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by formula (a), (b), (c), (d), (e), or (f):



wherein R_3 and R_4 are taken together and represent alkylidene or a heteroatom-containing alkylidene or R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxyalkylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminioalkyl, or di-alkylaminoalkyl;

with the proviso that if the first substituent is halogen or alkoxy, then the compound is disubstituted;






with the further proviso that if the compound is monosubstituted and has a first substituent at the 5 or 7 position, then the first substituent is a group represented by the formula (e) or (f);






and with the further proviso that if the compound is disubstituted and has a substituent present at the 7 position, then the substituent present at the 7 position is not a group represented by the formula (a) or (c).





14. (Original) The compound of claim 13, with the proviso that if the compound is disubstituted, then at least one of the substituents is a group represented by the formula (d) or (f).






15-108. (Canceled)







109. (Presently amended) A compound, or a pharmaceutically acceptable salt of the compound, having the formula:






























































































































































































110. (Presently amended) A compound, or a pharmaceutically acceptable salt of the compound, having the formula:



wherein A and B are:

A	B
-NH ₂	-NH ₂

-N(CH ₂ CH ₂ CH ₂ CH ₃) ₂	-N(CH ₂ CH ₂ CH ₂ CH ₃) ₂
-NHC ₆ H ₅	-NHC ₆ H ₅
-OC ₆ H ₅	-OC ₆ H ₅
-NH ₂	-N(CH ₂ CH ₂ CH ₂ CH ₃) ₂
-NH ₂	-N(CH ₂ CH ₂ CN)(CH ₂ CH ₂ OH)
-NH ₂	-N(CH ₂ CH ₂ CH ₂ CH ₃) ₂
-NHCH ₃	-NHCH ₃
-N(CH ₃) ₂	-N(CH ₃) ₂
-N(CH ₂ CH ₃) ₂	-N(CH ₂ CH ₃) ₂
-NHCH ₂ CH ₃	-NHCH ₂ CH ₃
-OCH ₃	-OCH ₃
-OCH ₂ CH ₃	-OCH ₂ CH ₃
-OCH ₂ CH ₂ OCH ₃	-OCH ₂ CH ₂ OCH ₃
	
-Cl	-Cl
-NHCH ₂ CH ₂ OH	-NHCH ₂ CH ₂ OH
-NHCH ₂ CH ₂ CH ₂ CH ₃	-NHCH ₂ CH ₂ CH ₂ CH ₃
-F	-OCH ₂ CH ₂ CH ₂ CH ₃
-F	-OCH(CH ₃) ₂
-F	-OCH ₂ CH(CH ₂ CH ₃)CH ₂ CH ₂ CH ₂ CH ₃
-F	-OCH ₂ CH ₂ OC ₆ H ₅
-F	-OCH ₂ CH=CH ₂
-F	-OCH ₂ CHCN

-F	$-\text{O}(\text{CH}_2)_3\text{OCH}_3$
-F	$-\text{O}(\text{CH}_2)_2\text{O}(\text{CH}_2)_2\text{OCH}_3$
-F	$-\text{OCH}_2\text{C}_6\text{H}_5$
-F	$-\text{OCH}_2\text{CH}_2\text{OH}$
-F	$-\text{OCH}_2(4\text{-chlorophenyl})$
-F	$-\text{OCH}_2\text{CH}_2\text{Cl}$
-F	$-\text{OCH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_3$
-F	$-\text{O}(\text{CH}_2)_5\text{CH}_3$
-F	 <p>The structure shows a benzimidazole ring system. The nitrogen atom at position 2 of the benzimidazole is connected to an ethoxy group (-OCH₂CH₂-). The benzimidazole ring consists of a benzene ring fused to an imidazole ring, with carbonyl groups at positions 1 and 3 of the imidazole ring.</p>
-F	 <p>The structure shows a 1,3-dioxolane ring (a five-membered ring with one oxygen atom). The ring is connected at position 2 to an ethoxy group (-OCH₂-). The ring is also connected at position 5 to a benzimidazole ring system, which has carbonyl groups at positions 1 and 3 of the imidazole ring.</p>
-F	$-\text{OCH}_2\text{CH}(\text{OH})\text{CH}_2\text{OCH}_3$
-F	$-\text{OCH}_2\text{CH}_2\text{OC}(\text{O})\text{C}_6\text{H}_5$
-F	$-\text{OCH}_2\text{CH}_2\text{OCH}_2\text{C}_6\text{H}_5$
-F	$-\text{OCH}_2\text{C}(\text{O})\text{OCH}_2\text{CH}_2\text{C}=\text{CH}_2$
-F	$-\text{OCH}_2\text{CH}_2\text{OCH}_3$
-F	$-\text{OCH}_2\text{CH}_2\text{C}_6\text{H}_5$
-F	$-\text{OCH}_3$
-F	$-\text{OCH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{CN}$
-Cl	$-\text{NHCH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_3$

$\text{-OCH}_2\text{CH}_2\text{CH}_2\text{CH}_3$	$\text{-NHCH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_3$
